ENOTPROST^® : DEPOSITED EXTRACT OF STANDARDISED FIREWEED WITH CLINICALLY PROVEN EFFICACY IN REDUCING THE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

Fireweed (Epilobium angustifolium) is a plant traditionally used to treat symptoms associated with benign prostatic hyperplasia (BPH). Fireweed exerts antioxidant, anti-inflammatory and antiproliferative properties thanks to its main biologically active components corresponding to flavonoids (myricetol derivatives), ellagitannins (ellagic acid and oenothein B) and phytosterols (β-sitosterol).

ENOTProst^® is a fireweed extract standardised to 15% oenothein B. This active ingredient contributes to fireweed's anti-proliferative action. On the one hand, it limits the production of dihydrotestosterone (DHT) by inhibiting 5α-reductase and, on the other, reduces the aromatisation of testosterone into oestrogen, hormones involved in stimulating prostate growth.

The efficacy of ENOTProst^® has been clinically demonstrated in reducing nocturia, post-micturition residual volume and improving quality of life in BPH.

A randomised, double-blind, placebo-controlled clinical trial of 128 patients supplemented daily with 500 mg ENOTProst^® for 6 months showed a significant 21.7% increase in the number of people who no longer needed to get up at night to urinate, compared with a 10.2% decrease in the placebo group¹.
In addition, the number of patients getting up three or more times a night was zero at the end of the study¹. ENOTProst^® therefore helps to improve sleep quality. Supplementation with ENOTProst^® is also associated with a significant increase in the number of patients with a low post-micturition residual volume (PMRV) and a reduction in the number of patients with a PMRV greater than 100 mL¹.

Improvement in quality of life was also assessed using the International Prostate Symptom Score (IPSS) questionnaire, which measures the severity of BPH symptoms. Supplementation with 500 mg ENOTProst^® showed an improvement in quality of life compared with the start of the study, with a significant reduction in the IPSS score of 15% (-2 points; p<0.01), while this score increased significantly in the placebo group after 6 months (p<0.01).

(1) Esposito, Cristina et al. “Epilobium angustifolium L. extract with high content in oenothein B on benign prostatic hyperplasia: A monocentric, randomized, double-blind, placebo-controlled clinical trial.” Biomedicine & pharmacotherapy vol. 138 (2021)
 ENOTProst® is a registered trademark of EPO S.r.l.